Chemistry:Rifaquizinone
From HandWiki
Rifaquizinone (RFQ, CBR-2092, TNP-2092) is an experimental antibiotic medication developed in China for the treatment of bacterial infections such as drug-resistant strains of Staphylococcus aureus. It is an orally active prodrug which is also a codrug, being cleaved inside the body to two active components, with half of the molecule being a rifamycin derivative, and the other half a quinolone antibiotic. It is in clinical trials for joint infections following surgery and acute bacterial skin and skin structure infections.[1][2][3][4]
See also
- Cefilavancin
References
- ↑ "Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates". Frontiers in Chemistry 9. 2021. doi:10.3389/fchem.2021.659845. PMID 33996753. Bibcode: 2021FrCh....9..317S.
- ↑ "P-1090. Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial". Open Forum Infectious Diseases 12 (Supplement_1). 29 January 2025. doi:10.1093/ofid/ofae631.1278.
- ↑ "P-1111. Efficacy of Intra-Articular Administration of Rifaquizinone in Rodent Models of Implant Infection Associated with Staphylococcus aureus". Open Forum Infectious Diseases 12 (Supplement_1). 29 January 2025. doi:10.1093/ofid/ofae631.1299.
- ↑ "Staph wars: the antibiotic pipeline strikes back". Microbiology 169 (9). September 2023. doi:10.1099/mic.0.001387. PMID 37656158.
 |  |
